Showing 9991-10000 of 15015 results for "reverse type I diabetes".
- New Research Links Childhood Asthma to Memory Challengeshttps://reachmd.com/news/new-research-links-childhood-asthma-to-memory-challenges/2468586/A recent study has identified a connection between asthma and memory difficulties in children, marking the first time these two conditions have been formally linked. Published in JAMA Network Open, the findings suggest that children with asthma may have a reduced ability to remember spec
- New Study Finds No Association Between Tobacco Smoke and Childhood Atopic Dermatitishttps://reachmd.com/news/new-study-finds-no-association-between-tobacco-smoke-and-childhood-atopic-dermatitis/2468587/A new study has found no evidence linking tobacco smoke exposure (TSE) to atopic dermatitis (AD) in children and adolescents. Following 10,521 individuals as part of the Avon Longitudinal Study of Parents and Children, researchers examined both active and passive TSE but observed no association w
- Modifiable Risk Factors Linked to Stroke Severityhttps://reachmd.com/news/modifiable-risk-factors-linked-to-stroke-severity/2468592/New research highlights the significant role of modifiable risk factors like high blood pressure, atrial fibrillation, and smoking in determining stroke severity. Published in Neurology, the American Academy of Neurology’s medical journal, this study suggests that individuals with these
- New Study Shows Virtual Cognitive Behavioral Therapy Reduces Suicide Risk in High-Risk Adultshttps://reachmd.com/news/new-study-shows-virtual-cognitive-behavioral-therapy-reduces-suicide-risk-in-high-risk-adults/2468596/As suicide rates continue to climb worldwide, mental health researchers are exploring innovative ways to reach those at risk. A new study from Ohio State University Wexner Medical Center and College of Medicine has found that delivering brief cognitive behavioral therapy (CBT) via video telehealt
- New Study Reveals Lifelong Factors in Healthy Brain Aginghttps://reachmd.com/news/new-study-reveals-lifelong-factors-in-healthy-brain-aging/2468594/A landmark 25-year research project has uncovered important insights into how brains age, revealing that cognitive resilience or decline can be significantly influenced by factors established as early as childhood. This study, conducted by the University of Edinburgh and published in Genomic
- Zasocitinib Effective in Moderate to Severe Psoriasis: Analysishttps://reachmd.com/news/study-zasocitinib-effective-moderate-severe-psoriasis/2468601/Results from a recent placebo-controlled trial of zasocitinib showed promise in improving skin clearance for patients with moderate to severe plaque psoriasis. The phase 2b study, conducted across multiple centers in the United States and Canada, included 259 patients treated over 12 week
- A Quarter of Pediatric Deaths at Hospitals Are Preventable, Study Findshttps://reachmd.com/news/a-quarter-of-pediatric-deaths-at-hospitals-are-preventable-study-finds/2468593/Your support helps us to tell the storyFrom reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro
- Study Links Severe AD with Need for Surgery in Glaucoma Patientshttps://reachmd.com/news/study-links-severe-ad-with-need-for-surgery-in-glaucoma-patients/2468588/Patients suffering from both severe atopic dermatitis (AD) and glaucoma are increasingly likely to need surgical intervention for the glaucoma depending on the severity of their AD, according to a new Journal of Glaucoma study.“Association of Atopic Dermatitis and Ris
- Amlitelimab Reduces AD Symptoms in Phase 2b Trialhttps://reachmd.com/news/amlitelimab-reduces-ad-symptoms-in-phase-2b-trial/2468589/Treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped in new research published in the Journal of Allergy and Clinical Immunology.Results from the pha
- Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024https://reachmd.com/news/roflumilast-cream-015-receives-glamours-best-eczema-product-award-2024/2468585/Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards. The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to